FFTY:NYE-Innovator IBD® 50 ETF (USD)

ETF | Mid-Cap Growth |

Last Closing

USD 26.97

Change

-0.14 (-0.52)%

Market Cap

N/A

Volume

0.10M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-07 )

Largest Industry Peers for Mid-Cap Growth

Symbol Name Price(Change) Market Cap
IWP iShares Russell Mid-Cap Growth..

-0.96 (-0.81%)

USD 15.11B
VOT Vanguard Mid-Cap Growth Index ..

-1.63 (-0.67%)

USD 14.24B
IJK iShares S&P Mid-Cap 400 Growth..

-0.63 (-0.68%)

USD 9.35B
XMMO Invesco S&P MidCap Momentum ET..

-0.75 (-0.62%)

USD 2.45B
IVOG Vanguard S&P Mid-Cap 400 Growt..

-0.82 (-0.71%)

USD 1.09B
ETHO Amplify ETF Trust

-0.51 (-0.87%)

USD 0.18B
CWS AdvisorShares Focused Equity E..

-0.56 (-0.82%)

USD 0.17B
IPO Renaissance IPO ETF

-0.24 (-0.57%)

USD 0.15B
BFOR Barron's 400 ETF

-0.69 (-0.95%)

USD 0.15B
PEXL Pacer US Export Leaders ETF

-0.30 (-0.59%)

USD 0.07B

ETFs Containing FFTY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Mid-Cap Growth) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.67% 69% C- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.67% 69% C- 61% D-
Trailing 12 Months  
Capital Gain 18.71% 56% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.71% 56% F 56% F
Trailing 5 Years  
Capital Gain -16.32% 33% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.32% 33% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike